Validation of a radiobiological model for use in the development of boost focal therapy for the treatment of prostate cancer

This retrospective study gathered post-implant dosimetry data and Prostate-Specific Antigen (PSA) profiles from patients that had previously received treatment for low risk prostate cancer using radioactive I-125 seeds. The study goal was to validate a previously developed radiobiological model, which was tested on more than 400 patients. The outcome of this study supports that the model is able to determine the optimal radioactive seed implant pattern that will deliver sufficient radiation dose to the tumour volume to ensure effective disease control, while minimizing doses to surrounding organs and non-cancerous prostate tissue.


Peter MacCallum Cancer Centre

Principal investigator/s

A/Prof Annette Haworth, Clinical Research Physicist

A/Prof Scott Williams, Radiation Oncologist

Radiation Oncology Lead, Urology Tumour Stream / Consultant Radiation Oncologist


A/Prof Annette Haworth

Principal Investigator - Clinical Research Physicist

Email: [email protected]

Publications & presentations

Haworth A, Williams S, Reynolds H, et al. (2013) Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. Brachytherapy. 12(6), 628-636.